Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation

Area of Science:

• Immunology
• Gene Therapy Safety

Background:

• Adeno-associated virus (AAV) gene therapy frequently triggers complement activation, especially with high-dose systemic administration.
• While some laboratory changes are expected pharmacodynamic effects, a subset of patients develops severe complement-mediated endothelial injury and thrombotic microangiopathy.

Purpose of the Study:

• To address inconsistent laboratory monitoring practices for complement activation in gene therapy.
• To propose a standardized framework for interpreting complement biomarkers to improve patient safety.

Main Methods:

• Review of emerging data on complement alternative pathway amplification in gene therapy.
• Integration of complement biomarkers with hematologic and renal indices.
• Emphasis on serial trends in laboratory values over isolated measurements.

Main Results:

• Early laboratory changes (thrombocytopenia, C3/C4 reduction) are common but not always indicative of toxicity.
• Alternative pathway activation correlates with the severity of complement-mediated injury.
• Fragmented interpretation of biomarkers can obscure early signs of pathologic escalation.

Conclusions:

• Standardized, integrated laboratory monitoring is crucial for early detection of adverse complement-mediated events in AAV gene therapy.
• A laboratory-centered framework can enhance patient safety as gene therapy use expands.